Cargando…

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

BACKGROUND: Triple-negative breast cancers (TNBCs) are a group of heterogeneous diseases with various morphology, prognosis, and treatment response. Therefore, it is important to identify valuable biomarkers to predict the therapeutic response and prognosis for TNBCs. Tumor-infiltrating lymphocytes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Miao, Tian, Tian, Rao, Jia, Xu, Xiaoli, Yu, Baohua, Yang, Wentao, Shui, Ruohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119339/ https://www.ncbi.nlm.nih.gov/pubmed/30170605 http://dx.doi.org/10.1186/s13000-018-0743-7

Ejemplares similares

Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers
por: Tian, Tian, et al.
Publicado: (2016)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes
por: Huang, Liang, et al.
Publicado: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
por: Kuroda, Hajime, et al.
Publicado: (2021)

Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
por: Wang, Yunxuan, et al.
Publicado: (2018)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
por: Abuhadra, Nour, et al.
Publicado: (2022)

Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer
por: Elghazawy, Hagar, et al.
Publicado: (2021)

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
por: Bao, Jean, et al.
Publicado: (2015)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Hong, Jin, et al.
Publicado: (2021)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
por: Čeprnja, Toni, et al.
Publicado: (2022)

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
por: Gorenšek, Rok, et al.
Publicado: (2023)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial
por: Abuhadra, Nour, et al.
Publicado: (2023)

An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer
por: Shui, Ruohong, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
por: Wang, Ruo-Xi, et al.
Publicado: (2022)

Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study
por: Van Bockstal, Mieke R., et al.
Publicado: (2021)

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
por: García-Teijido, Paula, et al.
Publicado: (2016)

Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas
por: Hidalgo, Jose Villacorta, et al.
Publicado: (2014)

Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization
por: Gomez-Macias, Gabriela Sofia, et al.
Publicado: (2020)

Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics
por: Balkenhol, Maschenka CA., et al.
Publicado: (2021)

Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
por: Gao, Guoxuan, et al.
Publicado: (2020)

The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy
por: Geršak, Klara, et al.
Publicado: (2023)

Prognostic value of extranodal extension in axillary lymph node-positive breast cancer
por: Ma, XiaoXi, et al.
Publicado: (2021)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
por: Fournier, Marcia V., et al.
Publicado: (2019)

Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI
por: Zhou, Zijian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_crmvqqa77isl4pkm67af3ogiif